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Abstract
Pediatric acute myeloid leukemia (AML) remains a fatal disease for at least 30% of patients, stressing the need for improved
therapies and better risk stratification. As proteins are the unifying feature of (epi)genetic and environmental alterations,
and are often targeted by novel chemotherapeutic agents, we studied the proteomic landscape of pediatric AML. Protein
expression and activation levels were measured in 500 bulk leukemic patients’ samples and 30 control CD34+ cell samples,
using reverse phase protein arrays with 296 strictly validated antibodies. The multistep MetaGalaxy analysis methodology
was applied and identified nine protein expression signatures (PrSIG), based on strong recurrent protein expression patterns. PrSIG were associated with cytogenetics and mutational state, and with favorable or unfavorable prognosis. Analysis
based on treatment (i.e., ADE vs. ADE plus bortezomib) identified three PrSIG that did better with ADE plus bortezomib
than with ADE alone. When PrSIG were studied in the context of cytogenetic risk groups, PrSIG were independently prognostic after multivariate analysis, suggesting a potential value for proteomics in combination with current classification
systems. Proteins with universally increased (n=7) or decreased (n=17) expression were observed across PrSIG. Certain
proteins significantly differentially expressed from normal could be identified, forming a hypothetical platform for personalized medicine.

Introduction
Pediatric acute myeloid leukemia (AML) is a heterogeneous disease resulting from clonal expansion of myeloid
precursors that have lost the ability to differentiate normally.1 Despite improvements in outcome, the 5-year overall survival of affected patients approximates 70% and
serious long-term complications are common among survivors.2 With the exception of acute promyelocytic leuke-

mia, leukemia with FLT3-internal tandem duplication (ITD)
mutations, and mixed phenotype acute leukemia, pediatric AML has been treated as a homogeneous disease, as
therapy does not differ based on the underlying mutations.
Many genetic “drivers” have been implicated in pediatric
AML disease pathology and risk stratification. However,
only a minority of these drivers have been exploited by
targeted therapeutic interventions.3 Current risk-stratification considers genetic abnormalities (e.g., inv (16),
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monosomy 7), but otherwise relies on early response to
therapy (minimal residual disease status). However, risk-

Methods

stratification is imperfect and outcome within risk groups Patients’ samples
is heterogeneous. Since many drivers may prove to be di- Peripheral blood samples were collected from 500 pedirectly “undruggable”, targeting downstream proteins may atric patients with de novo AML participating in the COG
AAML1031 (#NCT01371981) phase III clinical trial (n=483)9
be efficacious. This requires knowledge of the proteomic
or in older clinical trials (n=17), and 30 control CD34+ bone
landscape that emerges from the combined “net” conmarrow samples from healthy donors (20 children and 10
sequences of genetic and epigenetic events. However,
adults) between July 2011 and February 2017.9 Samples
little is known about the proteomic landscape in pediatric with <80% blasts were enriched for leukemic cells by
AML. Improved understanding of this might enhance pre- CD3/CD19 depletion. Samples were collected before the
treatment risk stratification and guide the selection of start of chemotherapy (n=500), and 10 hours (h) (n=463)
therapies against targetable molecular lesions, especially and 24 h (n=466) after the start of induction chemotherapy. At both 10 h and 24 h, one dose of each chemotheraagents targeting protein function.
10
Genomic mutations influence cellular physiology via al- peutic agent had been administered. Written informed
tered protein abundance or activity, but several factors consent was obtained in accordance with the Declaration
diminish the correlation between genetic alterations and of Helsinki and local institutional review boards.
protein effects, including the general lack of correlation Outcome data were restricted to 410 of the 483 patients
enrolled on the AAML1031 trial. Outcome was not deterbetween cellular messenger RNA (mRNA) abundance and
mined for 69 patients treated with ADE after trial closure
protein expression,4,5 and the inability to assess postby the Data and Safety Monitoring Board, and for four patranslational modifications of proteins with genomic techtients who did not meet eligibility criteria. Two-hundred
niques. In other tumor types, protein quantification patients received standard ADE induction therapy, includcommonly influences diagnosis, classification and therapy ing 36 who also received sorafenib (ADES), while 210 pa(e.g., estrogen and progestin receptors, programmed cell tients received ADEB. Induction therapy produced
death ligand 1).6,7 Despite these advantages, proteomics complete remission by the end of induction II in 348 (85%)
has not been used to guide AML therapy.
patients, 31 (8%) were either refractory or died early. ReWe previously performed a pilot study of the proteomic lapse occurred in 156 (45%) patients, and 286 (70%) were
landscape examining 194 proteins in 95 de novo pediatric still alive with a median follow-up of 4.4 years (range, 0.3AML patients using an approach that recognized protein 7.5 years). Outcome data were calculated as published
9
expression patterns within protein functional groups previously. Mutation data were available for CEBPA, NPM1,
KIT (exons 8 and 17) and FLT3-ITD.11
(PFG).8 After determining the characterization of each patient’s PFG, we built higher order structures based on
strong correlations between PFG patterns, recognizing
eight protein expression signatures (PrSIG) that were prognostic. Here, we used this same approach to prospectively
examine 500 pediatric AML patients treated on a
Children’s Oncology Group (COG) randomized phase III
clinical trial (AAML1031). The hypothesis tested in this trial
was that the addition of the proteasome inhibitor bortezomib could improve therapy based on Ara-C (cytarabine),
daunorubicin, and etoposide (ADE). This trial closed early
when it was determined that adding bortezomib to ADE
(ADEB) did not improve either event-free or overall survival
at 3 years across the entire group of patents. We aimed
to: (i) validate the ability to classify pediatric AML patients
based on proteomics in a larger cohort, with significantly
more protein targets; (ii) determine whether protein classification could enhance risk stratification; (iii) identify patients who could benefit from ADEB; and (iv) identify
additional targets for potential combination therapy.

Reverse phase protein microarray methodology
The methodology and validation of the reverse phase protein microarray (RPPA) technique, including antibody validation, are described elsewhere.12-14 Briefly, slides were
probed with 301 validated antibodies (Online Supplementary Table S1). Stained slides were analyzed using Microvigene® software version 3.0 (VigeneTech, Inc., Carlisle, MA,
USA) to produce quantified data. Samples were printed in
five serial dilutions and SuperCurve algorithms were used
to generate a single protein concentration value in log2
format.15 Loading control16 and topographical normalization17 were performed to account for protein concentration and background staining variations. Replicate-based
normalization18 was used to align samples from two different slides. Five antibodies were excluded for different
reasons yielding a final set of 296 antibodies used for
analysis.9 Median expression levels of the normal bone
marrow CD34+ samples were subtracted from the expression in the patients’ samples to equalize the median
of the control samples to zero.
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Figure 1. Computational MetaGalaxy work flow. Multistep analysis that starts with relative expression of 296 protein targets.
Proteins were allocated into 31 protein functional groups (PFG) based on their known functionality or strong correlation from the
dataset. The progeny clustering algorithm identified an optimal number of protein clusters (PrCL) in each PFG. Block clustering
was applied to a binary matrix indicating PrCL-membership for all patients, and identified the existence of protein constellations
(PrCON) (i.e., strongly correlated PrCL from various PFG). Patients who expressed similar combinations of PrCON were defined
as having a given protein expression signature (PrSIG).

pression (negatively or positively) between patients within
each PFG. PrCL numbers ranged from three to five per PFG
(Figure 2A) and the total number of PrCL was 116.
Principal component analysis was applied to graphically
compare patients’ PrCL expression patterns to those of
non-malignant CD34+ cells. Although the overall proteomic
profiles of the pediatric AML patients were distinct from
those of normal CD34+ cells (Online Supplementary Figure
S1), we found overlapping “normal-like” expression patterns for 31 (27%) of the PrCL (Figure 2A). In four PFG,
more than one cluster was defined as “normal-like”, and
in five PFG no “normal-like” pattern was found. PrCL without dominant co-localization to CD34+ samples on the
principal component plot were defined as “leukemia-specific”.
To visually map how proteins interact with other PFG
core-members and RPPA dataset proteins, networks were
generated for each PrCL. Proteins were connected if they
were known to interact with other proteins based on the
STRING database or correlation in our dataset. The median
protein expression was calculated for each PrCL and overlaid onto the networks to visualize relative expression.
Networks can be viewed online at: http://leukemiaproteinatlas.org/pediatric-aml/.
As an example, the PFG “Heat shock” comprises five antibodies recognizing total proteins and two recognizing
Results
phosphorylated proteins. We discerned four “Heat shock”
Correlation of protein expression identifies functional
PrCL (Figure 3A). Expression levels in PrCL-1 were identprotein patterns within a protein functional group
ified as most “normal-like” (Figure 3B). Protein networks
The 296 proteins that were analyzed in this study were al- were generated for the seven heat shock protein
located into 31 PFG (autophagy, cell cycle, metabolism, members. For PrCL-2 to PrCL-4, expression of HSPA1A_L
etc.).8,20,21 Clustering analysis identified an optimal number and HSBP1-pSer82 changed between the four PrCL, as did
of patterns (i.e., PrCL) of similar correlated protein ex- AKT1S1 (connected to HSF1 and HSF1-pSer326) and CAV1

Computational analysis
The MetaGalaxy computational analysis was done as published previously (Figure 1).8,21,22 It takes a multistep approach that starts with separating proteins into 31 PFG
based on prior knowledge from the literature or strong
correlations within this dataset (Online Supplementary
Table S1). K-means23 coupled with the progeny clustering
algorithm24 was applied to identify an optimal number of
protein clusters (PrCL), i.e., patient subgroups with a similar correlated protein expression profile within each PFG.
Collective PrCL-memberships for each patient were combined into a binary matrix. Block-clustering25 was used to
search for correlations between PrCL (protein expression
constellation [PrCON]), and to cluster patients with similar
PrCON-membership into a PrSIG. Statistical analyses were
performed in R version 1.3.959 2009-2020 (RStudio, Inc.,
Boston, MA, USA) or SAS version 9.4 (SAS Institute, Inc.,
Cary, NC, USA).
The remaining parts of the methods are described in the
Online Supplementary Material. Online Supplementary
Table S2 summarizes the Cox analyses for outcome reported in Figures 3D, 5, and Online Supplementary Figures
S3, S7 and S8.
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Figure 2. Protein functional group classification and similarity to that of normal CD34+ cells. (A) The progeny clustering
algorithm was applied to the 31 protein functional groups (PFG) and identified an optimal number of protein clusters (PrCL). PrCL
were compared with those of normal CD34+ cells using principal component analysis, (PCA) and classified as either “normallike” or “leukemia-like”. “Normal-like” patterns are represented by hatched boxes, “leukemia-specific” patterns by full boxes. (B,
C) PCA with each PrCL being assigned to a color within the PFG to illustrate its similarity to, or difference from, normal CD34+
cells. Two examples of PCA mapping include (B) cell cycle and (C) mTOR-signaling Normal CD34+ samples are represented by
small black squares and large black circles. There was no co-localization with CD34+ cells for cell cycle.

(connected to HSP90AA1_B1 and HSPA1_L1), showing that
associated nodes correlate with core-protein PFGmembers. Simplified versions of the networks are shown
for PrCL-1 and PrCL-4 (Figure 3C). It is important to note
that heatmaps presented in other analyses have typically
been median normalized to 0 with the variance set from
-1 to +1, so that all variables are shown as ranging from
the minimum to the maximum of the scale (color range).
In contrast, our expression levels are shown relative to
normal, and therefore may only use a portion of the scale
(color) range.

Protein clusters correlate with clinical outcome
To evaluate the effect of protein expression alone on
prognosis, PrCL were correlated to outcome. Seven (23%)
PFG were found to be significantly associated with outcome (Online Supplementary Figure S2). For instance,
heat shock PrCL were prognostic, in the whole group of
patients, for overall survival (P=0.004), event-free survival
(P=0.0009), and relapse risk (P=0.0016), as well as in patients treated with either ADE or ADEB (ADE: overall survival, P=0.0035; event-free survival, P=0.0097; relapse
risk, P=0.0207; ADEB: overall survival, P=0.0002; event-
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Figure 3. Analysis of the heat shock protein functional group. (A) Optimal number of four protein clusters (PrCL) was identified
as shown by the heatmap (annotation bar: PrCL-1 [red], PrCL-2 [pink], PrCL-3 [yellow] and PrCL-4 [light green]). (B) Principal
component analysis shows relative expression of the four clusters in relation to normal CD34+ cells (black squares). (C)
Simplified version of the protein networks for PrCL-1 and PrCL-4. Networks illustrate the median expression of protein functional
group (PFG) core-protein members (large nodes) in relation to associated proteins (small nodes). Interactions between nodes
are based on the literature (…), reverse phase protein microarray data (- - -) or both (—). Associated nodes with most differences
between PrCL-1 and PrCL-4 are selected. As an example, AKT1S1 and CAV1 both have relatively normal expression in PrCL-1, while
their expression is relatively high in PrCL-4. (D) Outcome data stratified by PrCL. Outcomes for all patients (upper left panel),
patients treated with ADE (upper middle panel) and those treated with ADEB (upper right panel). Lower panels show outcome
data in cluster 2 (left) and cluster 4 (right) for patients treated with ADE (dark blue) or ADEB (red).

free survival, P<0.0001; relapse risk, P=0.0009) (Figure
3D). When we compared outcome after ADE to that after
ADEB, patients with PrCL-2 significantly benefited from
ADEB (n=131, 5-year overall survival, 54% vs. 81%,
P=0.00087), whereas patients with PrCL-4 did worse
(n=35, 5-year overall survival, 100% vs. 67%, P=0.019).
Bortezomib had no effect on patients with PrCL-1 (n=91)
(P=0.190), which was an unfavorable prognostic indicator
after both ADE and ADEB; this cluster was characterized
by high-HSF1-pSer326 and HSB1-pSer82. Event-free survival and relapse risk curves are shown in Online Supplementary Figure S3. Online Supplementary Table S3 shows
the distribution across the PrCL and the different treatment arms.
We previously published that low HSF1-pSer326 was associated with a better outcome after ADEB.10 In the current analysis, this effect was true for PrCL-2 and PrCL-3
(characterized by low HSF1-pSer326), but was absent for
PrCL-4, which also had concomitant increased expression of HSPA1A_L, emphasizing that a simultaneous
integrated analysis of multiple proteins, rather than a
single protein, could identify more detailed protein expression patterns and better characterize subpopulations
that could benefit from the addition of novel agents.
Recurrences in protein patterns classify patients into
nine protein expression signatures
To obtain a more systemic understanding of the 116
identified PrCL, pattern recognition of the relations between PrCL from various PFG was done using co-clustering. PrCL-memberships for the 31 PFG were assigned
to all 500 pediatric AML patients and compiled in a binary
matrix (MetaGalaxy) (Figure 4). Optimization calculations8,22 identified 12 patterns of recurrent (i.e., correlated) PrCL, defined as PrCON. From this, nine PrSIG
were defined as clusters of patients who expressed similar combinations of PrCON. Robustness of the PrCON and
PrSIG was tested on a training set (n=355) and test set
(n=145) and showed high reproducibility (P<0.0001) (Online Supplementary Figure S4). Sets were created by
using random sampling.26 None of the PrCON was predominantly associated with the “normal-like” clusters
(P=0.200). The PrCL in each PrCON are listed in Online
Supplementary Table S4.

Protein expression partially correlates with cytogenetics
and mutational state, but not with gene expression
Correlation between mRNA expression from RNA-sequencing and RPPA protein abundance was determined for
205 total-proteins in 390 samples, with a mean correlation of 0.17. Thirty-four (17%) proteins were negatively correlated, while 83% were positively correlated (Online
Supplementary Figure S5).
We found associations between PrSIG and cytogenetics
and mutation states. Data were available for CEBPA, NPMI,
FLT3-ITD, KIT (exons 8 and 17), KRAS, NRAS, GATA2, PTPN11,
MYH11 and IDH1/2. Mutations present in ≤10 of the patients
were not analyzed (Table 1). Translocation t(8;21) was more
frequently detected in PrSIG-4 (35% vs. 6% overall)
(P=0.001). Inversion (16) was associated with PrSIG-1, -6
and -8 (25%, 25%, 30% vs. 14%, overall), but scarcely seen
in PrSIG-2, -3, -5 and -7 (2%, 5%, 0% and 3%) (P<0.001).
Normal karyotype (diploid) was enriched in PrSIG-3, -5
and -6 (59%, 42%, 38% vs. 28% overall) that shared
PrCON-3. Those three also had the highest frequencies of
CEBPA mutation (PrSIG-3) and FLT3-ITD (PrSIG-3, -5 and
-6). While the MLL-rearrangement (11q23) was not exclusive to the PrSIG-7 protein expression pattern, 85% of patients with this signature harbored the MLLrearrangement (vs. 18% overall). KIT mutations were
mostly in patients with PrSIG-4 and -6 (P=0.004), and
NRAS and MYH11 in those with PrSIG-1 (P=0.024, P=0.037,
respectively). Although only 3% (n=12) of the patients had
mutated GATA2, 19% of those with PrSIG-3 had this mutation. Patients with the fusion gene NUP98-KDM5A (n=4)
were all present in PrSIG-4 (P=0.007). NPM1, KRAS, PTPN11
and IDH were not associated with specific PrSIG.
Correlation with patients’ characteristics and clinical
variables
Patients aged ≤1 year at the time of diagnosis were most
frequently clustered in PrSIG-7 to -9, which are associated
with PrCON-5. Low white blood cell count (≤100,000
cells/μL) strongly correlated with PrCON-7, with 81-89%
of the patients in PrSIG-1 to -4 and -9 having a low white
blood cell count versus 76% overall (P=0.001). Gender, ethnicity, race and central nervous system status at the time
of diagnosis were not associated with any PrSIG or PrCON
(Online Supplementary Figure S6).
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Figure 4. MetaGalaxy analysis identified the existence of 12 protein constellations and nine protein expression signatures.
Block clustering was applied to a binary matrix constructed from 116 protein clusters (PrCL) from 31 protein functional groups
(PFG). Each column indicates one patient (n=500) and his or her PrCL-membership. This identified the existence of 12 protein
constellations (PrCON; horizontally); i.e., PrCL that strongly correlated with each other. Patients with a similar pattern of PrCON
were defined as having a given a protein expression signature (PrSIG; vertically). The annotation bar shows nine PrSIG,
cytogenetics (t(8;21) [red], inv(16) [yellow], normal karyotype [green]), MLL (11q23) rearrangement [black], -5, -7, +8 abnormalities
[light blue], and other [gray]), and mutational status for CEBPA, FLT3-ITD, FLT3-ITD high allelic ratio (≥0.1), NPM1 and KIT (exons
8 and 17) (wildtype [blue], mutated [yellow]). Those with unknown mutational status are represented in gray.

Protein expression signatures provide prognostic
information
PrSIG were associated with response to therapy (Figure 5A)
with greater spread in 5-year overall survival in ADEBtreated cases compared to ADE-treated cases (Online Supplementary Figure S7). Similar to what was previously done
with cytogenetics prognostication, we identified PrSIG associated with favorable (PrSIG-3), intermediate (PrSIG-1, 4, -6, -8, -9) and unfavorable (PrSIG-2, -5, -7) prognosis
(overall survival, P=0.007; event-free survival, P=0.046; relapse risk, P=0.045) (Figure 5B). PrSIG-risk groups did not
correlate with AAML1031 risk group stratification or conventional risk group stratification (Online Supplementary
Table S5). Unfavorable PrSIG remained an independent
prognostic factor using multivariate Cox regression analysis
in overall and event-free survival and relapse risk (Table

2A). PrSIG with poorest prognosis in ADE-treated patients
were PrSIG-5 to -8, all characterized by PrCON-4-membership. Addition of bortezomib was beneficial for 5-year
overall survival in PrSIG-6 (62% vs. 84%, n=41, P=0.07, hazard ratio [HR]=0.32) and PrSIG-8 (56% to 79%, n=72,
P=0.06, HR=0.43) (Figure 5C), and a similar trend was observed in PrSIG-7. As PrSIG-6 to -8 were most strongly associated with PrCON-11, we compared ADE versus ADEB in
the PrCON-11 PrSIG. Overall survival at 5 years increased
from 58% to 78% (P=0.011, HR=0.46). Across the nine PrSIG,
relapse risk showed a significant dispersion, ranging from
24% to 63% at 5-year complete remission (P=0.03). In
PrSIG-3, relapse risk decreased from 45% to 11% with ADEB
(n=21, P=0.09, HR=0.18), while PrSIG-6 patients did worse
with ADEB (36% vs. 12%, n=34, P=0.10, HR=3.54) (Figure 5C).
While analysis of CEBPA-mutated patients as a group did
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Table 1. Patients’ characteristics stratified by protein expression signatures.
Variable
Treatment
arm
(N=410)
Gender
(N=498)

ADE
ADEB
ADES

Total
S1
(N=500) (N=48)
40%
36%
51%
48%
9%
16%

S2
(N=55)
43%
50%
7%

S3
(N=39)
44%
44%
11%

S4
(N=53)
38%
57%
5%

S5
(N=85)
27%
55%
18%

S6
(N=54)
34%
49%
17%

S7
(N=40)
48%
52%
0%

S8
(N=83)
44%
54%
1%

S9
P
(N=43)
56%
44%
0.793
0%

Female

49%

56%

48%

46%

49%

56%

37%

48%

52%

47%

0.620

0-1
2-10
11+

12%
55%
33%

8%
54%
38%

11%
56%
33%

3%
72%
26%

11%
60%
28%

4%
56%
40%

7%
69%
24%

18%
45%
38%

23%
43%
34%

21%
49%
30%

0.007

Hispanic

20%

17%

26%

21%

30%

21%

20%

15%

14%

17%

0.479

American
Black

12%

8%

13%

10%

11%

13%

15%

8%

13%

16%

0.950

Positive

40%

42%

28%

21%

42%

47%

47%

33%

47%

36%

0.050

>100,000

24%

19%

15%

13%

11%

33%

30%

43%

31%

16%

0.001

M0
M1
M2
M4
M5
M6
M7

2%
22%
19%
24%
27%
1%
4%

0%
29%
14%
26%
17%
3%
11%

3%
31%
23%
17%
23%
0%
3%

4%
44%
41%
7%
0%
4%
0%

7%
36%
25%
18%
11%
0%
4%

5%
40%
25%
16%
11%
0%
4%

0%
14%
17%
40%
26%
0%
3%

0%
3%
3%
24%
69%
0%
0%

0%
3%
8%
38%
48%
0%
3%

3%
6%
28%
16%
31%
3%
13%

<0.001

28%

29%

31%

28%

22%

41%

40%

10%

16%

26%

0.002

16%
13%

19%
25%

21%
2%

13%
5%

35%
12%

16%
0%

8%
25%

3%
3%

10%
30%

21%
16%

Normal
karyotype

28%

27%

23%

59%

21%

42%

38%

5%

16%

16%

t(9;11)(p2
2;q23)/11
q23

18%

4%

23%

3%

10%

8%

6%

85%

28%

12%

-5, -7, or
+8

9%

4%

15%

3%

10%

11%

12%

3%

9%

12%

Other

15%

21%

17%

18%

13%

22%

12%

3%

7%

23%

Mutated

21%

25%

15%

31%

16%

39%

32%

5%

12%

10%

<0.001

Mutated

10%

13%

10%

11%

4%

16%

14%

0%

11%

7%

0.192

Mutated

9%

4%

4%

33%

6%

21%

4%

0%

4%

2%

<0.001

Mutated

4%

7%

4%

0%

5%

2%

13%

0%

3%

3%

0.125

Mutated

8%

13%

9%

4%

20%

6%

10%

3%

3%

6%

0.068

c-KIT
(combined) Mutated
(N=399)

12%

20%

11%

4%

25%

8%

23%

3%

6%

9%

0.004

Age (years)
Ethnicity
(N=497)
Race
(N=488)
CNS status
(at Dx)
(N=497)
WBC (at
study entry)
FAB
classification
(N=339)

AAML1031
risk group† High risk
(N=485)
t(8;21)
inv16

Cytogenetics
(N=492)

FLT3-ITD
(N=489)
NPM1
(N=483)
CEBPA
(N=483)
c-KIT
(exon 8)
(N=399)
c-KIT
(exon 17)
(N=399)
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KRAS
(N=390)
NRAS
(N=390)
KRAS
and/or
NRAS
(N=390)
PTPN11
(N=390)
MYH11
(N=390)
GATA2
(N=390)
IDH1/2
(combined)
(N=390)
NUP98KDM5A
(N=352)
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Mutated

7%

2%

7%

0%

3%

8%

8%

13%

13%

9%

0.291

Mutated

25%

42%

23%

12%

16%

16%

23%

32%

33%

27%

0.024

Mutated

31%

44%

27%

12%

18%

22%

28%

42%

41%

30%

0.012

Mutated

7%

2%

16%

0%

5%

5%

10%

10%

11%

0%

0.063

Mutated

4%

16%

5%

4%

0%

3%

3%

3%

3%

3%

0.037

Mutated

3%

0%

2%

19%

3%

5%

0%

0%

1%

3%

0.001

Mutated

4%

2%

0%

8%

5%

5%

0%

0%

6%

6%

0.455

Positive

1%

0%

0%

0%

11%

0%

0%

0%

0%

0%

0.007

†

AML1031 protocol risk group definition: low risk: inv(16)/t(16;16) or t(8;21), or NPM or CEBPA mutation; high risk: FLT3-ITD+ with high allelic
ratio ≥ 0.4, or monosomy 5/del5q or 7, without low-risk features. Unknown or unavailable values were not considered in P-value calculations
and are excluded from the results. ADE: Ara-C, daunorubicin, and etoposide); ADEB; ADE plus bortezomib; ADES: ADE plus sorafenib; Dx:
diagnosis; WBC: white blood cell count; FAB. French-American-British.

not show benefit from bortezomib,12 none of the patients
in PrSIG-3 relapsed or died after ADEB versus a 60% event
and relapse-rate (n=3/5, P=0.039, P=0.037, respectively)
with ADE (Figure 5D). Survival analysis stratified by PrSIGrisk restricted to patients with a normal karyotype again
identified low- versus high-risk AML patients (P=0.044)
(Online Supplementary Figure S8). Of note, while heat
shock proteins were strongly associated with outcome in
the above analysis, they were not among the main drivers
of PrCON and PrSIG clustering.

Proteins significantly different from normal can be
identified for each protein expression signature and
protein constellation
The majority of targeted drugs in development act on protein function. Recognition of proteins with an abnormal
expression could identify targets for therapy across AML
subgroups. We identified proteins significantly different
from normal for each PrSIG/PrCON (Figure 6) (available
online at: http://leukemiaproteinatlas.org/pediatric-aml/).
As an example, two proteins, VEGFR and PARP1, are shown
in particular, as they may also function as potential therapeutic targets for inhibitory drugs. Twenty-four proteins
Proteomics augment cytogenetic risk stratification
were identified as having universally higher (n=7) or lower
We analyzed AAML1031 low-risk patients (defined by
(n=17) expression across all PrSIG with vimentin (VIM)
inv(16)/t(16;16), t(8;21), NPM1 or CEBPA mutations) separately
most strongly expressed.
to determine whether proteomics were informative for outcome. We found stratification for event-free survival and
Proteins involved in cell cycle regulation and DNA
relapse risk by PrSIG with favorable prognosis in PrSIG-1, damage change following exposure to chemotherapy
3, -6 and -9 and unfavorable prognosis in PrSIG-5 and -7
To assess whether cells would adapt their PrSIG differ(overall survival, P=0.071; event-free survival, P=0.027; reentially following chemotherapy, unsupervised hierarchilapse risk, P=0.014) (Online Supplementary Figure S9). Cox cal clustering of pre-treatment and post-treatment
proportional hazards regression models identified unfavor- samples was performed. None of the expression patterns
able proteomic signatures as a significant independent was specific to a given time-point or treatment arm.
prognostic factor in multivariate analysis (Table 2B). Within Comparison of individual protein expression levels identthe AAML1031 high-risk patients (i.e., those with FLT3-ITD+ ified 87 (29%) proteins that had changed by 10 h after
high allelic ratio, monosomy 5 or 7 or del(5q), or minimal treatment and 173 (58%) by 24 h after treatment. Sixtyresidual disease >0.1% at end of induction 1) PrSIG were also seven (77%) proteins were changed at both time-points,
significantly prognostic. While prognosis of PrSIG-1, -3 and and were predominantly involved in the TP53 pathway
-6 was consistent between AAML1031 risk groups, prognosis (TP53, MDM4), DNA damage response (ATM, Chek2) and
of PrSIG-9 was favorable among the low-risk, but highly un- cell cycle regulation (Wee1, CCND3, RB1-pSer) (Online
favorable among the high-risk patients.
Supplementary Table S6).
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B
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D

Figure 5. Kaplan-Meier curves for overall survival, event-free survival and relapse risk. Left upper three panels: overall survival
curves (log-rank), right panels: relapse risk (Gray statistics). (A) Overall survival and relapse risk stratified by the nine protein
expression signatures (PrSIG). (B) Proteomic risk groups defined as “favorable”, “intermediate”, “unfavorable”. (C) Comparison of
outcomes in patients treated with ADE or. ADEB in PrSIG-8 (left) and PrSIG-3 (right). (D) Event-free survival and relapse risk for
CEBPA-mutated patients in PrSIG-3 treated with ADE (blue) or ADEB (red).
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Table 2. Multivariable analysis for overall survival, event-free survival and relapse risk, including proteomic-based
signatures.
A
Multivariate analysis, all patients (n=400)†
OS from study entry
N

HR

Intermediate

226

1

Favorable
Unfavorable
AAML1031 risk
group
Low

27
147

0.31
1.55

281

1

119

2.56

354
46

1
2.33

Negative

355

1

Positive

45

0.36

High

95% CI

EFS from study entry
P

HR

95% CI

P

N

HR

200

1

21
127

0.82
1.59

265

1

<0.001

83

1.10

0.73-1.66 0.658

<0.001

311
37

1
2.29

1.42-3.71 0.001

305

1

43

0.62

1
0.08-1.27
1.07-2.25

0.102
0.022

0.78
1.40

0.40-1.55
1.04-1.87

0.484
0.026

1
1.75-3.73

<0.001

1.76

0.001

1
2.60

1.30-2.39

RR from end of induction II
95% CI

P

0.35-1.90 0.643
1.12-2.25 0.010

Age (years old)
≥2
0-1
NPM1

1.43-3.77

1.77-3.82

1
0.15-0.88

0.026

0.52

0.30-0.92

0.026

0.33-1.15 0.129

B
Multivariate analysis, AAML1931 low risk patients (n=281)
OS from study entry
95% CI

EFS from study entry

N

HR

P

HR

95% CI

Intermediate

117

1

Favorable

98

0.58

0.30-1.13

0.112

0.72

0.46-1.11

Unfavorable

66

1.88

1.08-3.26

0.025

1.77

1.18-2.67

≥2

245

1

0-1

36

1.82

P

RR from end of induction II
N

HR

95% CI

P

110

1

0.137

90

0.57

0.35-0.95 0.029

0.006

65

1.66

1.07-2.58 0.025

233

1

32

2.36

Proteomic-SIG
1

Age (years old)
1
0.99-3.34

0.055

2.25

1.44-3.52

<0.001

1.42-3.92 0.001

†

Ten patients have unknown classification for protocol risk group and are excluded from analyses because all patients must have complete
data for a multivariable analysis. OS: overall survival; EFS: event-free survival; RR_ relapse risk; HR: hazard ratio; 95% CI: 95% confidence
interval: SIG: signatures.

When survival analysis was performed for each individual
protein (stratified by median, thirds or quartiles), a similar
number of proteins was prognostic within each group regardless of whether the pre-treatment or the post-treatment expression was assessed. Approximately 20% of the
proteins that were significantly prognostic before treatment, remained prognostic after treatment. Seven proteins were significantly prognostic at all three time-points
when considering all patients together; BCL2A1, CCND3,
CD74, EIF2S1, GSK3A_B, HSPB1.pSer82, and MKNK1. Nine
other proteins, mostly involved in protein translation or
signal transduction, were prognostic at both 10 h and 24
h after treatment, but not before treatment. These proteins were: ATF3, EIF2S1.pS51, EIF4EBP1, EIF4G1, HSF1,
MET.pY1230_1234_1235, PTEN, RPS6KB1, and YAP1.

Discussion
In this study, to our knowledge the largest proteomic
study in pediatric AML, we validated our central hypothesis that the genetic heterogeneity of pediatric AML coalesces into a finite number of recurrent protein
expression patterns. Unique to this study is the use of a
multistep protein analysis, which moves beyond individual
protein expression and activation, to a combined analysis
in functionally related protein groups, and then into a system spanning structure based on strongly correlated PrCL.
We believe that this is a more complete approach, utilizing
known functional interactions, and is superior to conventional unsupervised clustering which weights all proteins
equally and ignores known relationships. Furthermore, this

Haematologica | 107 October 2022

2339

ARTICLE - Proteomic landscape in pediatric AML

F.W. Hoff et al.

A

B

C

Figure 6. Protein expression significantly different from normal. (A) Protein expression deviated significantly from normal in
protein expression signature (PrSIG)-3 (P<0.05, and log2 change ≥0.50 log2). Proteins indicated by red circles are potentially
targetable. (B) Relative VEGFR (KDR) (left, potential target for PrSIG-2 to 4, and PrSIG-6 to -9) and PARP1 (right, target for patients
in PrSIG-3 to -5) protein expression levels across the nine PrSIG. (C) Twenty-four proteins with universally higher (n=7) or lower
(n=17) expression (P<0.05, and log2 change ≥0.50) compared to that in normal CD34+ cells. VIM (indicated by the red box) was
most strongly upregulated across the nine PrSIG.

study uses proteomics for the first time in samples collected from a phase III randomized clinical trial, and identified patients who responded well to a specific therapy.
Traditional risk stratification in pediatric AML considers selected cytogenetics and molecular features, and early response to induction chemotherapy, but predicts outcome
for only 40% of patients.32 When prognostically similar PrSIG
were grouped as “favorable”, “intermediate”, or “unfavorable”, we demonstrated increased prognostic significance
when added to traditional risk stratifying factors in multivariate analysis. PrSIG were more strongly predictive when
combined with AAML1031 risk groups, demonstrating that
adding proteomics to genetic risk-stratification can direct
therapy leading to improved outcome. Proteins were also
individually significantly prognostic, including several that
had previously been published as being so in adult AML.
We identified three PrSIG (PrSIG-3, -6, and -8; 34% of all
patients) that benefited from proteasome inhibitor ther-

apy, a finding not appreciated by analysis of the entire cohort. This finding suggests that proteomic analysis is able
to predict a-priori those who would benefit from a specific therapy. PrSIG-6 and -8 both contained PrCON-11 and
were characterized by upregulation of autophagy proteins
(ATG3, ATG7, BECN1).33 We hypothesize that these autophagy effectors are required for bortezomib-induced
autophagy, given that the ubiquitin-proteasome system
has active crosstalk with autophagy, and bortezomib
stimulates this compensatory autophagy mechanism resulting in cell death.34 PrCON-11 was associated with a
prevalence of M4/M5 (monocytic) patients and least
M0/M1/M2 cases (P<0.001) as well as a high frequency of
high white blood cell counts (P<0.001). In PrSIG-7, which
shares PrCON-11, a similar but less strong beneficial effect
of bortezomib was observed. Unlike PrSIG-6 and -8,
PrSIG-7 had higher phosphorylation levels of heat shock
binding protein 1 (HSPB1-pSer82), a strongly unfavorable
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prognostic factor in our dataset, but without a benefit
from proteasome inhibitor therapy. This protein could
possibly work by preventing the toxic build-up of misfolded proteins due to bortezomib.35 PrSIG-7 had a protein
expression profile suggesting high cell cycle turnover (high
CCND3, CDKN1B-pThr198, and RB1-phospho), high white cell
count, and a high frequency of MLL-rearrangements. This
highlights the need to apply a holistic system approach to
be able to predict response to drugs.
The importance of studying protein expression and activation is stressed by the low correlation (r=0.17) between protein and mRNA expression and the inability of mRNA data
to replicate protein-determined PrSIG. The lack of correlation was expected, as the presence of mRNA does not
imply that translation is occurring (non-coding RNA could
impede it); nor does it dictate the rate of translation or protein longevity after translation. Moreover, environmental effects from mesenchymal stromal cells, including
chemokine and cytokine production, affect how emerging
leukemia cells develop and behave. Nonetheless, PrSIG
were partially correlated with cytogenetics and mutational
state. “Driver” mutations would be expected to have a defining effect on biology/protein expression even though the
combination of other events might further alter these signals. For instance, the majority of PrSIG-7 (85%) had MLLrearrangements and, similar to the recognition of Ph+-like
acute lymphoblastic leukemia, this may point toward the
existence of MLL-like cases based on protein expression.
This study demonstrates that the “hallmarks of cancer”36,37
are achieved via different patterns of protein utilization
within the defined PrCON. As an example of the five apoptosis PFG used in this study, PrCON-6 demonstrated high
BH3 pro-apoptotic member activation (BAX, BBC3, and
BCL2L11) and simultaneously high expression of the antiapoptotic BH3-member MCL1, a protein associated with
resistance to chemotherapy.38 PrCON-11 demonstrated a
different pathway with high expression of autophagy proteins, but no associations with the other apoptotic PFG.
PrCON-9 had modest upregulation of autophagy proteins
and evidence of increased spontaneous apoptosis proteins (high PARP1-cleavage, apoptosis-occurring PrCL-2,
and PrCL-3).
Targeted therapies offer the promise of improved outcome, often with less toxicity, compared to current
chemotherapy, but an effective means of matching the
appropriate patient to the correct agent hampers implementation. To select drugs rationally for specific subgroups of patients, we identified proteins that were
expressed significantly differently between cases of AML
and normal subjects, raising the hypothesis that those
could be targeted by inhibitory/replacement or (re)activation agents, potentially even combined with targeting genetic molecular events (e.g., midostaurin [FLT3] enasidenib
[IDH2], or ivosidenib [IDH1]). Online Supplementary Table

S7 lists matched proteins and drugs used in the clinical
setting. If validated, rapid real-time classification, based
on measuring expression of a restricted number of proteins
with the highest discriminative value between PrSIG (a
“classifier set”), could enable PrSIG determination and facilitate initial therapy selection as well as classification.
We identified 24 universally altered proteins, identifying
novel potential targets for all patients. The most highly
overexpressed protein was VIM, a protein involved in
epithelial-to-mesenchymal transition. The role for VIM in
AML is uncertain, but there is evidence that epithelial-tomesenchymal transition occurs in hematologic malignancies.39,40 Fluvastatin targets VIM via caspase-3-mediated
proteolysis,41,42 and prior trials in AML demonstrated that
the addition of pravastatin to idarubicin and high-dose cytarabine counteracted the chemoresistance associated
with the defensive adaptation of increasing cellular cholesterol.43,44 MCL1, previously found to be upregulated in six
of the eight PrSIG in another study,8 was also universally
highly expressed, most prominently in PrSIG-7 to -9, which
had the highest frequency of infants, a historically chemoresistant population.8,45 MCL1 is also strongly associated
with chemoresistance to venetoclax. Although clinical trials
have evaluated the benefit of (combinational) treatment
with venetoclax in adults and relapsed pediatric AML, no
studies evaluating the effect of venetoclax in de novo pediatric AML have yet been published. Our finding predicts for
lower efficacy in pediatric de novo AML, and suggests that
venetoclax could be combined with MCL1 inhibitors.
A final feature of this RPPA study was the measurement of
therapy effects on protein expression over time. We expected to find specific treatment-induced changes in protein expression, and different adaptation of proteins across
the PrSIG; however, changes were limited to DNA damage,
cell cycle regulation, protein translation and histone modification pathways. This likely reflects the presence of many
pre-apoptotic cells trying to repair DNA damage. Single-cell
proteomics might better profile post-treatment AML heterogeneity and predict which changes are associated with
resistance or relapse by identifying “survivor cells”, which
cannot be identified in studies of bulk cells.46 Proteomics
may also enable identification and analysis of stem cell proteomics, which differ from bulk cells.47-49 Moreover, unbiased
approaches such as mass spectrometry, which allow evaluation of global proteomics, might also be of use.50
In summary, we confirmed the existence of recurrent protein patterns in pediatric AML which enabled separation
of AML patients into recurrent PrSIG that were prognostic,
particularly when combined with known pediatric AML risk
factors. We identified PrSIG that benefited from ADEB, and
postulate that recognition of abnormal proteins can aid in
risk stratification and therapy selection in pediatric, and
perhaps adult AML.
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